RLAY - Relay Therapeutics: A 'Concept' Stock

2024-06-24 14:02:01 ET

Summary

• Today, we take a look at Relay Therapeutics, Inc., which is focused on developing small molecule drug candidates for oncology and genetic diseases using its proprietary Dynamo Platform.
• The company believes this platform could significantly improve the candidate selection process, and Relay has myriad candidates in various stages of development.
• Relay Therapeutics' most advance candidates are RLY-2608 targeting a form of breast cancer and RLY-4008 aimed at a form of bile duct cancer.
• Analyst firms are high on the company's prospects, and the company ended the first quarter with nearly $750 million of cash on its balance sheet.
• An analysis around Relay Therapeutics follows in the paragraphs below.

Today, we put Relay Therapeutics, Inc. ( RLAY ) in the spotlight. This clinical-stage precision medicines company has seen several analyst firms reissued Buy ratings on its stock so far in June. Cantor Fitzgerald also mentioned the company as a potential buyout target in March of this year. An analysis follows below....

For further details see: